ATE279185T1 - 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden - Google Patents
2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werdenInfo
- Publication number
- ATE279185T1 ATE279185T1 AT96942623T AT96942623T ATE279185T1 AT E279185 T1 ATE279185 T1 AT E279185T1 AT 96942623 T AT96942623 T AT 96942623T AT 96942623 T AT96942623 T AT 96942623T AT E279185 T1 ATE279185 T1 AT E279185T1
- Authority
- AT
- Austria
- Prior art keywords
- octylphenyl
- propane
- ethyl
- amino
- disruption
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000000987 immune system Anatomy 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 238000010322 bone marrow transplantation Methods 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP34250395 | 1995-12-28 | ||
| PCT/JP1996/003757 WO1997024112A1 (en) | 1995-12-28 | 1996-12-24 | External preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE279185T1 true ATE279185T1 (de) | 2004-10-15 |
Family
ID=18354257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96942623T ATE279185T1 (de) | 1995-12-28 | 1996-12-24 | 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6121329A (de) |
| EP (1) | EP0812588B1 (de) |
| AT (1) | ATE279185T1 (de) |
| AU (1) | AU705320B2 (de) |
| CA (1) | CA2213989C (de) |
| CZ (1) | CZ285953B6 (de) |
| DE (1) | DE69633613T2 (de) |
| ES (1) | ES2230571T3 (de) |
| HU (1) | HU224814B1 (de) |
| IL (1) | IL121625A (de) |
| NZ (1) | NZ324453A (de) |
| PT (1) | PT812588E (de) |
| RU (1) | RU2156127C2 (de) |
| SI (1) | SI0812588T1 (de) |
| SK (1) | SK282225B6 (de) |
| WO (1) | WO1997024112A1 (de) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241272A (ja) * | 1996-07-18 | 2002-08-28 | Mitsubishi Pharma Corp | 医薬処方組成物 |
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| US6476004B1 (en) | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
| GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| DE69840169D1 (de) * | 1997-02-27 | 2008-12-11 | Novartis Ag | Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid |
| WO1999055332A1 (en) | 1998-04-27 | 1999-11-04 | Fujisawa Pharmaceutical Co., Ltd. | Medicinal compositions |
| US20020006901A1 (en) * | 1999-02-05 | 2002-01-17 | Aldo T. Iacono | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
| US7683044B2 (en) * | 1999-03-25 | 2010-03-23 | Center For Molecular Medicine And Immunology | Sphingomyelin therapy of autoimmune disease |
| ATE334686T1 (de) * | 1999-03-25 | 2006-08-15 | Ct Molecular Med & Immunology | Sphingomyelin enthaltende zusammensetzung zur verbesserung der tumortherapie |
| AU8533101A (en) | 2000-08-31 | 2002-03-13 | Merck & Co Inc | Phosphate derivatives as immunoregulatory agents |
| CA2435739A1 (en) * | 2001-02-22 | 2002-09-06 | Novartis Ag | Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function |
| US20030124174A1 (en) * | 2001-10-25 | 2003-07-03 | Endo Pharmaceuticals, Inc | Method for treating non-neuropathic pain |
| RU2330839C2 (ru) * | 2002-01-11 | 2008-08-10 | Санкио Компани, Лимитед | Производные аминоспиртов или производные фосфорных кислот и фармацевтические композиции, содержащие указанные производные |
| WO2003094965A2 (en) | 2002-05-08 | 2003-11-20 | Neuronova Ab | Modulation of neural stem cells with s1p or lpa receptor agonists |
| RU2220738C1 (ru) * | 2002-08-30 | 2004-01-10 | Гапонюк Петр Яковлевич | Средство для лечения ринита |
| KR20050092429A (ko) * | 2003-01-22 | 2005-09-21 | 니찌방 가부시기가이샤 | 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법 |
| GB0307866D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
| DE202004021680U1 (de) | 2003-04-08 | 2010-04-22 | Novartis Ag | Feste pharmazeutische Zusammensetzung |
| RU2233163C1 (ru) * | 2003-04-30 | 2004-07-27 | Государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт" | Способ лечения акантолитической пузырчатки |
| US7524887B2 (en) | 2003-06-06 | 2009-04-28 | Sanofi-Aventis Deutschland Gmbh | 2-amino-1,3-propanediol compounds for the treatment of acute pain |
| EP1484057A1 (de) * | 2003-06-06 | 2004-12-08 | Aventis Pharma Deutschland GmbH | Verwendung von 2-amino-1,3-propandiolderivaten zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen |
| BRPI0414193A (pt) * | 2003-09-09 | 2006-10-31 | 3M Innovative Properties Co | composição antimicrobiana, kit antimicrobiano e métodos de usar a composição e de aplicar uma composição antimicrobiana a um substrato |
| US20050058673A1 (en) | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
| GB0324210D0 (en) | 2003-10-15 | 2003-11-19 | Novartis Ag | Organic compounds |
| GB0329498D0 (en) * | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| GB0500020D0 (en) * | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
| TWI355934B (en) | 2004-02-24 | 2012-01-11 | Sankyo Co | Pharmaceutical composition for treatment or prophy |
| US20050232894A1 (en) * | 2004-04-20 | 2005-10-20 | Weiner Gregory M | Antimicrobial skin treatment composition and methods for producing and using an antimicrobial skin treatment composition |
| PT1773307E (pt) * | 2004-07-30 | 2015-01-14 | Novartis Ag | Formulações de compostos à base de 2-amino-1,3- propanodiol |
| WO2006041942A2 (en) * | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
| US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| SG187468A1 (en) * | 2004-11-29 | 2013-02-28 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
| US20080233053A1 (en) * | 2005-02-07 | 2008-09-25 | Pharmalight Inc. | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients |
| GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| KR20070113281A (ko) | 2005-03-10 | 2007-11-28 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 항미생물성 조성물 및 방법 |
| JP2008533048A (ja) | 2005-03-10 | 2008-08-21 | スリーエム イノベイティブ プロパティズ カンパニー | 耳の感染症の治療方法 |
| EP2497460A1 (de) | 2005-03-10 | 2012-09-12 | 3M Innovative Properties Co. | Verfahren zur Reduktion von mikrobieller Kontamination |
| US20060229364A1 (en) * | 2005-03-10 | 2006-10-12 | 3M Innovative Properties Company | Antiviral compositions and methods of use |
| WO2006102611A2 (en) * | 2005-03-24 | 2006-09-28 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of leukemia |
| CN101222939B (zh) * | 2005-07-13 | 2010-11-24 | 参天制药株式会社 | 眼科用防腐组合物 |
| WO2007098139A2 (en) * | 2006-02-21 | 2007-08-30 | The Ohio State University Research Foundation | Anticancer agents |
| WO2007143081A2 (en) * | 2006-06-02 | 2007-12-13 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of lymphoid malignancies |
| US20080075793A1 (en) * | 2006-09-21 | 2008-03-27 | Dunshee Wayne K | Antiviral compositions and methods of use |
| PT2465492E (pt) | 2007-10-12 | 2015-10-15 | Novartis Ag | Composições que compreendem moduladores de receptores de esfingosina-1-fosfato (s1p) |
| RU2361604C1 (ru) * | 2007-10-29 | 2009-07-20 | Федеральное агентство по высокотехнологичной медицинской помощи Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" (ФГУ УрНИИДВиИ Росмедтехнологий) | Способ лечения атопического дерматита |
| WO2009115954A1 (en) | 2008-03-17 | 2009-09-24 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective s1p1 receptor agonist |
| JP2012523458A (ja) * | 2009-04-13 | 2012-10-04 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | タンパク質ホスファターゼ２ａ活性化剤 |
| CA2759011A1 (en) * | 2009-04-17 | 2010-10-21 | The Ohio State University Research Foundation | Antiadhesion agents |
| EP2456752A2 (de) * | 2009-07-24 | 2012-05-30 | ratiopharm GmbH | Verfahren zur herstellung von fingolimodsalzen |
| CN101966145A (zh) * | 2010-09-21 | 2011-02-09 | 浙江大学 | 2-氨基-2-(2-[4-辛基苯基]乙基)-1,3-丙二醇盐酸盐制剂及其制备方法 |
| WO2012071524A1 (en) | 2010-11-24 | 2012-05-31 | Ratiopharm Gmbh | Arylsulfonate salts of fingolimod and processes for preparation thereof |
| US8309768B2 (en) | 2010-11-29 | 2012-11-13 | The Ohio State University Research Foundation | FTY720-derived anticancer agents |
| JP6111202B2 (ja) | 2011-01-07 | 2017-04-05 | ノバルティス アーゲー | 免疫抑制製剤 |
| JO3177B1 (ar) | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
| RU2496486C1 (ru) | 2012-07-11 | 2013-10-27 | Александр Васильевич Иващенко | Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение |
| WO2014117035A1 (en) | 2013-01-24 | 2014-07-31 | Transderm, Inc. | COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS |
| US10022340B2 (en) | 2013-10-11 | 2018-07-17 | Teikoku Pharma Usa, Inc. | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same |
| US10675254B2 (en) | 2013-10-11 | 2020-06-09 | Teikoku Seiyaku Co., Ltd. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| AU2018205253B2 (en) | 2017-01-06 | 2022-01-13 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
| US10798783B2 (en) * | 2017-02-15 | 2020-10-06 | Continuous Composites Inc. | Additively manufactured composite heater |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| CN113491696A (zh) * | 2017-07-05 | 2021-10-12 | 江阴优培尔康药业有限公司 | 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂 |
| EP3817743A4 (de) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | Wasserfreie zusammensetzungen von mtor-hemmern und verfahren zur verwendung |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU374086A1 (ru) * | 1971-06-11 | 1973-03-20 | ЛЕКАРСТВЕННОЕ СРЕДСТВО''^ --''ОсНАЯ'•'^^^bju;r---jc^'-;^..':. :0 •--.:А |:'*''~'"~~ •' - ——«-.«aSJ^iH. | |
| SE7510988L (sv) * | 1975-10-01 | 1977-04-02 | Draco Ab | Nya farmaceutiskt aktiva foreningar |
| US4861800A (en) * | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
| EP0356399A3 (de) * | 1988-08-26 | 1991-03-20 | Sandoz Ag | Substituierte 4-Azatricyclo (22.3.1.04.9) octacos-18-en-Derivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen |
| EP0501579A1 (de) * | 1991-02-28 | 1992-09-02 | Merck Frosst Canada Inc. | Naphthalinlactone als Inhibitoren der Leukotrien-Biosynthese |
| IL102236A0 (en) * | 1991-06-27 | 1993-01-14 | Ltt Inst Co Ltd | Topical preparations containing cyclosporin |
| IT1252866B (it) * | 1991-12-31 | 1995-06-28 | Lifegroup Spa | N-acilderivati di aminoalcooli con acidi policarbossilici atti alla modulazione dei mastociti nei processi infiammatori su base neuroimmunogenica |
| IT1252865B (it) * | 1991-12-31 | 1995-06-28 | Lifegroup Spa | N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni |
| EP0627406B1 (de) * | 1992-10-21 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1, 3- propandiolverbindung und immunosuppressium |
| JPH06256182A (ja) * | 1993-03-05 | 1994-09-13 | L T T Kenkyusho:Kk | 外用製剤 |
| JPH07188046A (ja) * | 1993-12-27 | 1995-07-25 | L T T Kenkyusho:Kk | シクロスポリン含有外用治療薬及びその製造方法 |
| EP0694308A4 (de) * | 1994-02-17 | 1997-09-10 | Shiseido Co Ltd | Cyclosporin-enthaltene emulsionszusammensetzung |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
-
1996
- 1996-12-24 AT AT96942623T patent/ATE279185T1/de active
- 1996-12-24 US US08/894,728 patent/US6121329A/en not_active Expired - Lifetime
- 1996-12-24 WO PCT/JP1996/003757 patent/WO1997024112A1/ja not_active Ceased
- 1996-12-24 IL IL12162596A patent/IL121625A/en not_active IP Right Cessation
- 1996-12-24 PT PT96942623T patent/PT812588E/pt unknown
- 1996-12-24 DE DE69633613T patent/DE69633613T2/de not_active Expired - Lifetime
- 1996-12-24 ES ES96942623T patent/ES2230571T3/es not_active Expired - Lifetime
- 1996-12-24 CZ CZ972704A patent/CZ285953B6/cs not_active IP Right Cessation
- 1996-12-24 AU AU11729/97A patent/AU705320B2/en not_active Expired
- 1996-12-24 HU HU9800034A patent/HU224814B1/hu unknown
- 1996-12-24 CA CA002213989A patent/CA2213989C/en not_active Expired - Lifetime
- 1996-12-24 SI SI9630694T patent/SI0812588T1/xx unknown
- 1996-12-24 RU RU97115893/14A patent/RU2156127C2/ru active
- 1996-12-24 EP EP96942623A patent/EP0812588B1/de not_active Expired - Lifetime
- 1996-12-24 SK SK1157-97A patent/SK282225B6/sk not_active IP Right Cessation
- 1996-12-24 NZ NZ324453A patent/NZ324453A/xx not_active IP Right Cessation
-
2000
- 2000-06-12 US US09/592,550 patent/US6197829B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9800034A3 (en) | 1999-12-28 |
| WO1997024112A1 (en) | 1997-07-10 |
| PT812588E (pt) | 2005-01-31 |
| EP0812588B1 (de) | 2004-10-13 |
| SI0812588T1 (en) | 2005-02-28 |
| IL121625A0 (en) | 1998-02-08 |
| ES2230571T3 (es) | 2005-05-01 |
| EP0812588A1 (de) | 1997-12-17 |
| CZ285953B6 (cs) | 1999-12-15 |
| HU224814B1 (en) | 2006-02-28 |
| SK115797A3 (en) | 1998-02-04 |
| AU705320B2 (en) | 1999-05-20 |
| NZ324453A (en) | 2000-03-27 |
| RU2156127C2 (ru) | 2000-09-20 |
| AU1172997A (en) | 1997-07-28 |
| IL121625A (en) | 2001-09-13 |
| CA2213989C (en) | 2007-05-29 |
| US6197829B1 (en) | 2001-03-06 |
| US6121329A (en) | 2000-09-19 |
| HUP9800034A2 (hu) | 1999-05-28 |
| DE69633613T2 (de) | 2006-02-09 |
| DE69633613D1 (de) | 2004-11-18 |
| EP0812588A4 (de) | 2002-11-06 |
| CZ270497A3 (cs) | 1998-01-14 |
| SK282225B6 (sk) | 2001-12-03 |
| CA2213989A1 (en) | 1997-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69633613D1 (de) | 2-Amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-diol enthaltendes Arzneimittel zur topischen Anwendung zur Behandlung von Erkrankungen die durch eine Störung des Immunsystems hervorgerufen werden | |
| DE69815122D1 (de) | Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen | |
| BRPI9504791B8 (pt) | composto de polipeptídeo e composição farmacêutica. | |
| DE3684190D1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
| DE69825292D1 (de) | Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen | |
| ATE83659T1 (de) | Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus. | |
| RU94027680A (ru) | Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы | |
| GR1002451B (el) | Αντιφλεγμονωδεις συνθεσεις που εχουν ως βαση ενεργα συστατικα ορισμενων βοτανων χρησιμοποιουμενες για σκοπους ιατρικους και κτηνιατρικους, και μεθοδοι παρασκευης φαρμακων και σκευασματων για τους παραπανω σκοπους. | |
| DE69602412D1 (de) | Ophthalmische Zubereitung zur Behandlung oder Prävention von trockenem Auge und Krankheiten, die dadurch verursacht werden, enthaltend 12-Sulfodehydroabietsäure | |
| RU95109905A (ru) | Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта | |
| FR2453650A1 (fr) | Medicament a base de derives du cholecalciferol, utilisable pour regler le metabolisme des os chez les homeothermes | |
| RU93032613A (ru) | Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата | |
| DE69819110D1 (de) | Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus | |
| ATE265851T1 (de) | Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden | |
| ATE157871T1 (de) | Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind | |
| ATE316379T1 (de) | Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen | |
| ES2145902T3 (es) | Aplicacion del riluzole en el tratamiento de las enfermedades mitocondriales. | |
| US5648397A (en) | Pharmaceutical composition and methods for using it | |
| KR100227125B1 (ko) | 미포자충감염을치료하기위한벤즈이미다졸구충제의용도 | |
| WO1998038854A1 (en) | Pharmaceutical composition and methods for using it | |
| FR2437832A1 (fr) | Medicament a base de p-tolyl diiodomethylsulfone utile notamment pour le traitement des infections cutanees provoquees par les levures et les champignons | |
| ATE331523T1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| BR9809127A (pt) | Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente | |
| ATE293445T1 (de) | Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
| DE68916443D1 (de) | Arzneimittel zur behandlung von kryptosporidiose. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0812588 Country of ref document: EP |